selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patients Pipeline molecule to treat T cell mediated autoimmune diseases San Diego, CA, USA, and Munich, Germany – January 5, 2024 – selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T cell mediated autoimmune diseases, today announced that management will present … Read more
